Fierce Biotech

Kailera CEO 'knew we were in a good spot' before obesity biotech's record-breaking $625M IPO

Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its ...
BioSpace

UPDATE: Kailera breaks biotech IPO record with $625M debut

Kailera Therapeutics is advancing a pipeline of obesity drugs, led by the GLP-1/GIP dual agonist ribupatide, which the ...
Fierce Biotech

Was Big Pharma’s ‘unusually aggressive’ M&A spree to blame for March IPO drought?

It was as recently as February that biotech CEOs were talking enthusiastically to Fierce about a positive “shift in the ...
FiercePharma

A cut above: Veradermics locks in $256M IPO and shares spike

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind Rogaine—is well coiffed to tap into the increasingly lush opportunity for hair ...
Hosted on MSN

Four biotech companies on track to IPO this week despite the government shutdown

This could be the biggest week for biotech IPOs in years — even if the government remains shuttered temporarily. Government funding lapsed this past Saturday, sparking a partial government shutdown ...
GEN

StockWatch: Withdrawals, Share Prices Suggest a Still-Cloudy Outlook for IPOs

Two withdrawals of recently submitted initial public offering (IPO) filings by drug developers, plus a dearth of new filings this month, suggest that the outlook for biopharma IPOs remains cloudy, ...